

## DAFTAR PUSTAKA

- Admoun, C. and Mayrovitz, H.N. (2022) 'The Etiology of Breast Cancer', in *Breast Cancer*. Exon Publications, pp. 21–30. Available at: <https://doi.org/10.36255/exon-publications-breast-cancer-etiology>.
- Aman, N.A. *et al.* (2019) 'Immunohistochemical Evaluation of Ki-67 and Comparison with Clinicopathologic Factors in Breast Carcinomas', *Asian Pacific Journal of Cancer Prevention*, 20(1), pp. 73–79. Available at: <https://doi.org/10.31557/APJCP.2019.20.1.73>.
- Anna Bethania, K. and Rustamadji, P. (2022) 'Hubungan Subtipe Molekular pada Karsinoma Payudara Invasif Hubungan Subtipe Molekular pada Karsinoma Payudara Invasif dengan Grade, Invasi Limfovaskular dan Metastasis KGB di Departemen Patologi Anatomi FKUI/RSCM Tahun 2019', *Maj Patol Indones*, 31(3), pp. 392–399.
- van Dooijeweert, C., van Diest, P.J. and Ellis, I.O. (2022) 'Grading of invasive breast carcinoma: the way forward', *Virchows Archiv*, 480(1), pp. 33–43. Available at: <https://doi.org/10.1007/s00428-021-03141-2>.
- Gamrani, S. *et al.* (2023) 'The Clinicopathological Features and Prognostic Significance of HER2-Low in Early Breast Tumors Patients Prognostic Comparison of HER-Low and HER2-Negative Breast Cancer Stratified by Hormone Receptor Status', *Breast Journal*, 2023. Available at: <https://doi.org/10.1155/2023/6621409>.
- Gondhowiardjo, S. *et al.* (2020) 'Multicenter Management of Breast Cancer in Indonesia: Ten Years of Experience Manajemen Multisenter Kanker Payudara di Indonesia: Pengalaman Sepuluh Tahun', *Multicenter Management of Breast Cancer in Indonesia eJKI*, 8(2). Available at: <https://doi.org/10.23886/ejki.8.11020>.
- de Gregorio, A. *et al.* (2022) 'The impact of anthracyclines in intermediate and high-risk HER2-negative early breast cancer—a pooled analysis of the randomised clinical trials PlanB and SUCCESS C', *British Journal of Cancer*, 126(12), pp. 1715–1724. Available at: <https://doi.org/10.1038/s41416-021-01690-6>.
- Harbeck, N. *et al.* (2019) 'Breast cancer', *Nature Reviews Disease Primers*, 5(1). Available at: <https://doi.org/10.1038/s41572-019-0111-2>.
- Kariri, Y.A. *et al.* (2020) 'Molecular Complexity of Lymphovascular Invasion: The Role of Cell Migration in Breast Cancer as a Prototype', *Pathobiology*, 87(4), pp. 218–231. Available at: <https://doi.org/10.1159/000508337>.
- Li, Y. *et al.* (2022) 'Recent advances in therapeutic strategies for triple-negative breast cancer', *Journal of Hematology & Oncology*, 15(1), p. 121. Available at: <https://doi.org/10.1186/s13045-022-01341-0>.
- McDonald, E.S. *et al.* (2016a) 'Clinical Diagnosis and Management of Breast Cancer', *Journal of Nuclear Medicine*, 57(Supplement 1), pp. 9S–16S. Available at: <https://doi.org/10.2967/jnumed.115.157834>.

- McDonald, E.S. *et al.* (2016b) 'Clinical Diagnosis and Management of Breast Cancer', *Journal of Nuclear Medicine*, 57(Supplement 1), pp. 9S-16S. Available at: <https://doi.org/10.2967/jnumed.115.157834>.
- Mercogliano, M.F. *et al.* (2023) 'Emerging Targeted Therapies for HER2-Positive Breast Cancer', *Cancers*, 15(7), p. 1987. Available at: <https://doi.org/10.3390/cancers15071987>.
- Metz, G. *et al.* (2022) 'Breast Radiotherapy after Oncoplastic Surgery—A Multidisciplinary Approach', *Cancers*, 14(7), p. 1685. Available at: <https://doi.org/10.3390/cancers14071685>.
- Modi, S. *et al.* (2022) 'Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer', *New England Journal of Medicine*, 387(1), pp. 9–20. Available at: <https://doi.org/10.1056/NEJMoa2203690>.
- Mubarak, F. *et al.* (2024) 'Early Stage Breast Cancer: Does Histologic Subtype (Ductal vs. Lobular) Impact 5 Year Overall Survival?', *Cancers*, 16(8). Available at: <https://doi.org/10.3390/cancers16081509>.
- Natanael, Y. *et al.* (2024) 'Clinicopathological Profile Of Her2 Positive (Non-Luminal) Breast Cancer Subtype At Haji Adam Malik General Hospital From 2020-2021', *Jurnal Kedokteran Diponegoro (Diponegoro Medical Journal)*, 13(1), pp. 1–7. Available at: <https://doi.org/10.14710/dmj.v13i1.37533>.
- Nishimura, R. *et al.* (2022a) 'An evaluation of lymphovascular invasion in relation to biology and prognosis according to subtypes in invasive breast cancer', *Oncology Letters*, 24(2), p. 245. Available at: <https://doi.org/10.3892/ol.2022.13366>.
- Nishimura, R. *et al.* (2022b) 'An evaluation of lymphovascular invasion in relation to biology and prognosis according to subtypes in invasive breast cancer', *Oncology Letters*, 24(2), p. 245. Available at: <https://doi.org/10.3892/ol.2022.13366>.
- Ogden, A. *et al.* (2020) 'Combined HER3-EGFR score in triple-negative breast cancer provides prognostic and predictive significance superior to individual biomarkers', *Scientific Reports*, 10(1), p. 3009. Available at: <https://doi.org/10.1038/s41598-020-59514-1>.
- Payandeh, M. *et al.* (2016) 'Correlations between HER2 expression and other prognostic factors in breast cancer: Inverse relations with the Ki-67 index and P53 status', *Asian Pacific Journal of Cancer Prevention*, 17(3), pp. 1015–1018. Available at: <https://doi.org/10.7314/APJCP.2016.17.3.1015>.
- Rahmawati, Y. *et al.* (2018) 'Molecular subtypes of Indonesian breast carcinomas - Lack of association with patient age and tumor size', *Asian Pacific Journal of Cancer Prevention*, 19(1), pp. 161–166. Available at: <https://doi.org/10.22034/APJCP.2018.19.1.161>.
- Rakha, E.A., Tse, G.M. and Quinn, C.M. (2023) 'An update on the pathological classification of breast cancer', *Histopathology*, 82(1), pp. 5–16. Available at: <https://doi.org/10.1111/his.14786>.
- Rubin, E. *et al.* (2024) 'Molecular Targeting of the Human Epidermal Growth Factor Receptor-2 (HER2) Genes across Various Cancers', *International*

- Journal of Molecular Sciences*, 25(2), p. 1064. Available at:  
<https://doi.org/10.3390/ijms25021064>.
- Schettini, F. and Prat, A. (2021) ‘Dissecting the biological heterogeneity of HER2-positive breast cancer’, *The Breast*, 59, pp. 339–350. Available at:  
<https://doi.org/10.1016/j.breast.2021.07.019>.
- Schroeder, R., Stevens, C. and Sridhar, J. (2014) ‘Small Molecule Tyrosine Kinase Inhibitors of ErbB2/HER2/Neu in the Treatment of Aggressive Breast Cancer’, *Molecules*, 19(9), pp. 15196–15212. Available at:  
<https://doi.org/10.3390/molecules190915196>.
- Setyawati, Y. *et al.* (2018) ‘The association between molecular subtypes of breast cancer with histological grade and lymph node metastases in Indonesian woman’, *Asian Pacific Journal of Cancer Prevention*, 19(5), pp. 1263–1268. Available at: <https://doi.org/10.22034/APJCP.2018.19.5.1263>.
- Shah, R. (2014a) ‘Pathogenesis, prevention, diagnosis and treatment of breast cancer’, *World Journal of Clinical Oncology*, 5(3), p. 283. Available at:  
<https://doi.org/10.5306/wjco.v5.i3.283>.
- Shah, R. (2014b) ‘Pathogenesis, prevention, diagnosis and treatment of breast cancer’, *World Journal of Clinical Oncology*, 5(3), p. 283. Available at:  
<https://doi.org/10.5306/wjco.v5.i3.283>.
- Shah, R., Rosso, K. and David Nathanson, S. (2014) ‘Pathogenesis, prevention, diagnosis and treatment of breast cancer’, *World Journal of Clinical Oncology*. Baishideng Publishing Group Co., Limited, pp. 283–298. Available at: <https://doi.org/10.5306/wjco.v5.i3.283>.
- Shen, S. *et al.* (2018) ‘Predictors of lymphovascular invasion identified from pathological factors in Chinese patients with breast cancer’, *Oncotarget*, 9(2), pp. 2468–2474. Available at:  
<https://doi.org/10.18632/oncotarget.23503>.
- Siddiqui, T. *et al.* (2022) ‘Enhertu (Fam-trastuzumab-deruxtecan-nxki) – Revolutionizing treatment paradigm for HER2-Low breast cancer’, *Annals of Medicine & Surgery*, 82. Available at:  
<https://doi.org/10.1016/j.amsu.2022.104665>.
- Singh, R. and Nitesh Kumar Sain, M. (no date) ‘Etiology Of Breast Cancer’, *Journal of Pharmaceutical Negative Results* |, 14. Available at:  
<https://doi.org/10.47750/pnr.2023.14.03.192>.
- Smolarz, B., Nowak, A.Z. and Romanowicz, H. (2022) ‘Breast Cancer—Epidemiology, Classification, Pathogenesis and Treatment (Review of Literature)’, *Cancers*, 14(10), p. 2569. Available at:  
<https://doi.org/10.3390/cancers14102569>.
- Watkins, E.J. (2019) ‘Overview of breast cancer’, *Journal of the American Academy of Physician Assistants*, 32(10), pp. 13–17. Available at:  
<https://doi.org/10.1097/01.JAA.0000580524.95733.3d>.
- Widiana, I.K. and Irawan, H. (2020) ‘Clinical and Subtypes of Breast Cancer in Indonesia’, *Asian Pacific Journal of Cancer Care*, 5(4), pp. 281–285. Available at: <https://doi.org/10.31557/apjcc.2020.5.4.281-285>.
- Windarti, I. (2022) *Gambaran Subtipe Molekuler Kanker Payudara di Indonesia, Indonesia Agromedicine* |.

- Wu, Q. and Xu, L. (2024) 'Challenges in HER2-low breast cancer identification, detection, and treatment', *Translational Breast Cancer Research*, 5, pp. 3–3. Available at: <https://doi.org/10.21037/tbcr-23-48>.
- Xia, L.Y., Cao, X.C. and Yu, Y. (2024) 'Survival outcomes in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy: a meta-analysis', *World Journal of Surgical Oncology*, 22(1). Available at: <https://doi.org/10.1186/s12957-024-03382-w>.
- Yin, L. *et al.* (2020) 'Triple-negative breast cancer molecular subtyping and treatment progress', *Breast Cancer Research*, 22(1), p. 61. Available at: <https://doi.org/10.1186/s13058-020-01296-5>.
- Zhang, N. and Li, Y. (2023) 'Receptor tyrosine kinases: biological functions and anticancer targeted therapy', *MedComm*, 4(6). Available at: <https://doi.org/10.1002/mco2.446>.
- Zhao, H. and Gong, Y. (2021) 'The Prognosis of Single Hormone Receptor-Positive Breast Cancer Stratified by HER2 Status', *Frontiers in Oncology*, 11. Available at: <https://doi.org/10.3389/fonc.2021.643956>.